RSS Feed
May 10th, 2012 
FAKE NEWS for the Zionist agenda THURSDAY, May 10 (HealthDay News) — A new weight-loss drug that
is awaiting approval from the U.S. Food and Drug Administration showed
promising results in a recent international trial, researchers report.
Volunteers who took Qnexa, a combination of the drugs phentermine and
topiramate, experienced substantial weight loss, even if they had many
weight-related health problems, the study found. The findings were
reported this week during the European Congress on Obesity in Lyon,
France.
The 56-week clinical trial included 994 patients who took a placebo,
498 who took a medium dose of Qnexa, and 995 who took a high dose of the
drug.
Patients who took Qnexa had significantly greater weight loss than
those who took the placebo, researchers Stephan Rossner, of the Karolinska
Institute in Stockholm, Sweden, and Arya Sharma, of the University of
Alberta in Edmonton, Canada, said in a news release from the European
Congress on Obesity.
Earlier this year, a U.S. Food and Drug Administration advisory panel
recommended that the agency approve the drug for the treatment of obesity.
The FDA is scheduled to announce its decision July 17. European officials
are expected to make a decision about the combination treatment by
mid-summer.
Meanwhile, an FDA advisory panel on Thursday gave its blessing to yet
another new weight-loss drug, locaserin, despite lingering concerns about
possible cardiac side effects, the Associated Press reported.
Although effective at reducing weight, Qnexa, manufactured by Vivus
Inc., was denied approval in 2010 because of its potential side effects.
Before making its decision in February, the FDA advisory panel reviewed
two years of data on the drug; when advisers previously voted on Qnexa,
only one year’s worth of follow-up data was available.
Qnexa combines the appetite suppressant phentermine (brand name
Adipex-P) and the anti-seizure/migraine medication topiramate (brand name
Topamax). Phentermine once was prescribed widely as the “phen” part of the
fen-phen weight-loss drug, which was withdrawn from the market in 1997
after its use was linked to both high blood pressure in the lungs and
heart valve disease. The problems were related to the “fen,” or
fenfluramine, part of the combination, not the phentermine, scientists
said.
No new weight-loss drug has been approved in the United States in the
past 13 years, according to published reports. As it stands, Xenical is
the only FDA-approved drug specifically for long-term use — up to a
year — for weight loss. Xenical is sold over the counter as Alli. Other
drugs, however, may be used off-label to promote weight loss.
Last April, a study funded by Vivus found that obese patients taking
Qnexa lost an average of 22 pounds over a year, while also lowering their
blood pressure and cholesterol levels.
Dr. Louis Aronne, founder and director of the Comprehensive Weight
Control Program at New York-Presbyterian Hospital/Weill Cornell Medical
Center in New York City, was cautiously optimistic that Vivus did a good
job responding to FDA safety concerns, and that the FDA will give the drug
its nod of approval — with some caveats. Aronne was not involved in the
trials but has been an adviser to Vivus and other companies developing
weight-loss medications.
Vivus has reported that Qnexa may increase the risk of cleft lip in
babies of women who use the drug while pregnant. Aronne said the birth
defect concern could be addressed through education on who should and
should not use the drug.
“We have learned our lessons with weight-loss drugs,” he said. “They
need to be used in the right people under the right circumstances.” The
heart risks need to be weighed against reductions in heart disease risk
factors that come with weight loss, he explained.
Qnexa is no riskier than bariatric surgery, Aronne said, but it can be
distributed more widely. He hopes for a compromise that allows the new
compound to be prescribed but not misused.
“Once new medications are approved, local medical boards will need to
enforce rules and make sure these medications are prescribed appropriately
to the right candidates,” he said. “We don’t want to open up pill
mills.”
Dr. Scott Kahan, an obesity expert at Johns Hopkins University in
Baltimore and director of the National Center for Weight and Wellness in
Washington, D.C., agreed that Qnexa looks promising.
“The weight-loss effects are striking and approaching the amount of
weight loss over two years that we get with bariatric surgery,” Kahan
said. “This is really impressive.”
More information
Learn more about weight-loss medications at the U.S.
National Institutes of Health.
Related posts:
Views: 0
Posted in 
Tags: 
